This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Tuesday's Health Winners & Losers

Acadia Pharmaceuticals' (ACAD) shares were up more than 15% after an analyst said the recent drop in the company's stock presents an opportunity to buy.

"We believe that Acadia has an emerging pipeline with five promising clinical programs targeting large central nervous system markets such as schizophrenia and Parkinson's disease," wrote Banc of America Securities biotech analyst David Witzke in a research report. He pointed out that the stock is down about 64% since its equity offering in April. He initiated coverage of the stock with a buy rating and set a price target of $10. Shares advanced 83 cents to $6.32.

Genzyme (GENZ) published results of a clinical trial involving its drug Tolevamer for diarrhea caused by the bacteria Clostridium difficile, sending the shares 1.3% higher to $67.37.

According to data from the trial, in which 300 patients received either Genzyme's Tolevamer or the antibiotic vancomycin, patients saw similar results, with the results indicating a possible reduction in the recurrence rate with the Genzyme drug. Vancomycin is currently the only FDA-approved drug to treat the infection.

Biopharmaceutical company Novavax (NVAX) shares were up 13% to $3.21 after an upgrade from RBC Capital Markets. While analyst Ken Trbovich notes that the company's quarterly results were weaker than expected, "with the stock trading near $3 per share, it no longer carries the significant downside risk that lead us to rate NVAX shares underperform," Trbovich wrote. The analyst raised his rating on the stock to sector-perform.

Among other health stocks on the move were Hospira (HSP), down 1.9% to $34.80, Tenet Healthcare (THC), whose shares sank 3.4% to $7.29, and Novogen (NVGN), whose stock was 2.2% lower at $10.22.

Elsewhere, Osteotech (OSTE) gained 7.1% to $3.92, Cytokinetics (CYTK) was up 5.9% to $5.59, CAS Medical Systems (CASM) rose 4.8% to $6.07, New River Pharmaceuticals (NRPH) soared 13.8% to $26.20, Rotech Healthcare (ROHI) climbed 3.3% to $1.25, and AMN Healthcare Services (AHS) was up 1.5% to $22.24.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs